{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:38:18Z","timestamp":1780576698624,"version":"3.54.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jaad.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T11:41:54Z","timestamp":1596800514000},"page":"1738-1748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist"],"prefix":"10.1016","volume":"83","author":[{"given":"Antonio","family":"Martinez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cuenca-Barrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinidad","family":"Montero-Vilchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.jaad.2020.08.006_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2020.08.006_bib3","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2020.08.006_bib4","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1111\/jdv.16472","article-title":"Urticarial eruption in COVID-19 infection","volume":"34","author":"Henry","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.006_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-444-64029-1.00002-3","article-title":"Fetal toxicology","volume":"162","author":"van de Bor","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.jaad.2020.08.006_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjd.19163","article-title":"Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases","volume":"183","author":"Galv\u00e1n Casas","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib7","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/jdv.16470","article-title":"Comment on: cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies","volume":"34","author":"Fernandez-Nieto","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.006_bib8","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1111\/jdv.16523","article-title":"Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection","volume":"34","author":"van Damme","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaad.2009.11.686","article-title":"Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases","volume":"62","author":"Peroni","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jaad.2020.08.006_bib15","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","article-title":"Retraction\u2014hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"395","author":"Mehra","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jaad.2020.08.006_bib16","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMc2021225","article-title":"Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19","volume":"382","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/1346-8138.14156","article-title":"Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: a case report and review of the published work","volume":"45","author":"Matsuda","year":"2018","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib19","doi-asserted-by":"crossref","first-page":"e13380","DOI":"10.1111\/dth.13380","article-title":"Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine","volume":"33","author":"Schwartz","year":"2020","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.jaad.2020.08.006_bib20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0961203319879987","article-title":"Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption","volume":"28","author":"Takamasu","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2020.08.006_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13383","article-title":"A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic?","author":"Kutlu","year":"2020","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2020.08.006_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0961203319854139","article-title":"A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus","volume":"28","author":"Shindo","year":"2019","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib23","doi-asserted-by":"crossref","first-page":"e224619","DOI":"10.1136\/bcr-2018-224619","article-title":"Hydroxychloroquine-induced inverse psoriasis","volume":"12","author":"Ullah","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"15","key":"10.1016\/j.jaad.2020.08.006_bib24","first-page":"1887","article-title":"Hydroxychloroquine-induced psoriasis-form erythroderma in a patient with systemic lupus erythematosus","volume":"131","author":"Wang","year":"2018","journal-title":"Chin ed J"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ijd.12231","article-title":"Synthetic antimalarial drugs and the triggering of psoriasis\u2014do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria?","volume":"53","author":"Gravani","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol Rep"},{"issue":"12","key":"10.1016\/j.jaad.2020.08.006_bib27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/0961203317700486","article-title":"Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases","volume":"26","author":"Bahloul","year":"2017","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.jaad.2020.08.006_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamadermatol.2013.709","article-title":"Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study","volume":"149","author":"Cacoub","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib29","first-page":"207","article-title":"Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation","volume":"18","author":"Girijala","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib30","first-page":"212","article-title":"Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis","volume":"97","author":"Pearson","year":"2016","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0301-0546(06)73537-6","article-title":"Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient","volume":"34","author":"P\u00e9rez-Ezquerra","year":"2006","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","article-title":"Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"Stewart","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jdv.12655","article-title":"Heparin-induced skin necrosis","volume":"30","author":"Sator","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MOH.0000000000000273","article-title":"Management of heparin-induced thrombocytopenia","volume":"23","author":"Warkentin","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.006_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/jmm.0.000565","article-title":"A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective","volume":"66","author":"Rabaan","year":"2017","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4081\/monaldi.2005.632","article-title":"An overview on severe acute respiratory syndrome (SARS)","volume":"63","author":"Hui","year":"2005","journal-title":"Monaldi Arch Chest Dis"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib39","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib40","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"19","key":"10.1016\/j.jaad.2020.08.006_bib41","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib42","first-page":"97","article-title":"Maculo-papular rash induced by lopinavir\/ritonavir","volume":"15","author":"Calista","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0b013e3181646d5a","article-title":"Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir\/ritonavir in antiretroviral-experienced HIV-infected children","volume":"27","author":"Rudin","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"18","key":"10.1016\/j.jaad.2020.08.006_bib44","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/QAD.0b013e328010f212","article-title":"Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00002030-200203080-00023","article-title":"Inflammatory oedema associated with lopinavir-including HAART regimens in advanced HIV-1 infection: report of 3 cases","volume":"16","author":"Eyer-Silva","year":"2002","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00002030-200104130-00028","article-title":"Inflammatory oedema of the legs: a new side-effect of lopinavir","volume":"15","author":"Lascaux","year":"2001","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.jaad.2020.08.006_bib47","first-page":"742","article-title":"Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient","volume":"6","author":"Chrysos","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib48","first-page":"28","article-title":"Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART","volume":"9","author":"Bongiovanni","year":"2003","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2020.08.006_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13476","article-title":"Cutaneous side-effects of the potential covid-19 drugs","author":"T\u00fcrsen","year":"2020","journal-title":"Dermatol Ther"},{"issue":"21-22","key":"10.1016\/j.jaad.2020.08.006_bib50","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00508-017-1268-x","article-title":"Anti-HCV treatment with ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir is associated with increased bile acid levels and pruritus","volume":"129","author":"Stauber","year":"2017","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1601-0825.2001.70401.x","article-title":"Orofacial effects of antiretroviral therapies","volume":"7","author":"Scully","year":"2001","journal-title":"Oral Dis"},{"issue":"22","key":"10.1016\/j.jaad.2020.08.006_bib52","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","article-title":"Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children","volume":"367","author":"Achan","year":"2012","journal-title":"N Engl J Med"},{"issue":"7-8","key":"10.1016\/j.jaad.2020.08.006_bib53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1345\/aph.10386","article-title":"Recurrent ingrown toenails secondary to indinavir\/ritonavir combination therapy","volume":"35","author":"James","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.006_bib54","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study","volume":"70","author":"Arabi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.006_bib55","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib56","doi-asserted-by":"crossref","first-page":"e1977","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev Med Virol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1046\/j.1365-2133.2003.05481.x","article-title":"Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin","volume":"149","author":"Kerl","year":"2003","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib58","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1365-2133.2004.05957.x","article-title":"Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment","volume":"150","author":"V\u00e1zquez-L\u00f3pez","year":"2004","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000353160","article-title":"Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin","volume":"228","author":"Patrk","year":"2014","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2020.08.006_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1155\/2009\/651952","article-title":"A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin","volume":"23","author":"Mistry","year":"2009","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/1203475415595775","article-title":"Cutaneous adverse events in chronic hepatitis c patients treated with new direct-acting antivirals: a systematic review and meta-analysis","volume":"20","author":"Patel","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib63","first-page":"76","article-title":"Tamiflu: what dermatologists need to know","volume":"9","author":"Bergstrom","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"85","key":"10.1016\/j.jaad.2020.08.006_bib64","first-page":"182","article-title":"Oseltamivir: cutaneous and neurological adverse effects in children","volume":"15","year":"2006","journal-title":"Prescrire Int"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib65","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.jaad.2020.08.006_bib67","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jaad.2020.08.006_bib68","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib69","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/jdv.16387","article-title":"Cutaneous manifestations in COVID-19: a first perspective","volume":"34","author":"Recalcati","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.006_bib70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jaad.2020.08.006_bib71","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr Med Chem"},{"issue":"15","key":"10.1016\/j.jaad.2020.08.006_bib72","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Davey","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib73","doi-asserted-by":"crossref","first-page":"E1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"issue":"8","key":"10.1016\/j.jaad.2020.08.006_bib75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jiac.2014.04.006","article-title":"Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor","volume":"20","author":"Lin","year":"2014","journal-title":"J Infect Chemother"},{"issue":"12","key":"10.1016\/j.jaad.2020.08.006_bib76","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/jmv.24585","article-title":"Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain","volume":"88","author":"Pernas","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2020.08.006_bib77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial","volume":"11","author":"Tashima","year":"2014","journal-title":"AIDS Res Ther"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib78","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jac\/dkn292","article-title":"Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection","volume":"62","author":"Borras-Blasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jaad.2020.08.006_bib79","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1111\/j.1365-2230.2009.03508.x","article-title":"Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus","volume":"34","author":"Pahk","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"19","key":"10.1016\/j.jaad.2020.08.006_bib80","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4143\/crt.2015.017","article-title":"Severe imatinib-associated skin rash in gastrointestinal stromal tumor patients: management and clinical implications","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.jaad.2020.08.006_bib82","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/ijd.13931","article-title":"Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature","volume":"57","author":"Di Tullio","year":"2018","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib83","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ced.13361","article-title":"Imatinib-induced pseudoporphyria","volume":"43","author":"Martinez-Mera","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib84","first-page":"189","article-title":"Imatinib mesylate-induced lichenoid drug eruption","volume":"99","author":"Penn","year":"2017","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.jaad.2020.08.006_bib85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","article-title":"Adverse skin effects of imatinib, a tyrosine kinase inhibitor","volume":"105","author":"Pretel-Irazabal","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.24894","article-title":"Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia","volume":"93","author":"Shi","year":"2018","journal-title":"Am J Hematol"},{"issue":"10229","key":"10.1016\/j.jaad.2020.08.006_bib87","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib88","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5114\/reum.2019.87616","article-title":"Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy","volume":"57","author":"Czekalska","year":"2019","journal-title":"Reumatologia"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib89","first-page":"625","article-title":"Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000001361","article-title":"Subcutaneous tocilizumab in monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs in Latin American patients with moderate to severe active rheumatoid arthritis: a multicenter, phase IIIb study","author":"Mysler","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19841796","article-title":"New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review","volume":"11","author":"Del Giorno","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib92","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.reuma.2016.10.008","article-title":"Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis\u2014case report","volume":"14","author":"Rosa-Goncalves","year":"2018","journal-title":"Reumatol Clin"},{"issue":"11","key":"10.1016\/j.jaad.2020.08.006_bib93","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/1756-185X.12658","article-title":"Tocilizumab-induced pustular drug eruption","volume":"20","author":"Mori","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib94","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib95","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00296-019-04259-y","article-title":"The right place of interleukin-1 inhibitors in the treatment of Beh\u00e7et's syndrome: a systematic review","volume":"39","author":"Bettiol","year":"2019","journal-title":"Rheumatol Int"},{"issue":"39","key":"10.1016\/j.jaad.2020.08.006_bib96","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.006_bib97","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/imj.13538","article-title":"Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Beh\u00e7et disease uveitis and concomitant bladder papillary carcinoma","volume":"47","author":"Orlando","year":"2017","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib98","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jaad.2020.08.006_bib101","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamadermatol.2014.109","article-title":"Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema","volume":"150","author":"Miyamoto","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib102","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib103","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.006_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2020.08.006_bib105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jdcr.2020.04.015","article-title":"Morbilliform exanthem associated with COVID-19","volume":"6","author":"Najarian","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib106","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1111\/jdv.16471","article-title":"A distinctive skin rash associated with coronavirus disease 2019?","volume":"34","author":"Mah\u00e9","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.08.006_bib107","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19\u2014preliminary report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.08.006_bib108","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jaad.2020.04.016","article-title":"Reply to \u201cCOVID-19 can present with a rash and be mistaken for Dengue\u201d: petechial rash in a patient with COVID-19 infection","volume":"83","author":"Jimenez-Cauhe","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.006_bib109","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2020.04.018","article-title":"A dermatologic manifestation of COVID-19: transient livedo reticularis","volume":"83","author":"Manalo","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.006_bib110","first-page":"118","article-title":"Treatments for COVID-19: emerging drugs against the coronavirus","volume":"91","author":"Pot\u00ec","year":"2020","journal-title":"Acta Biomed"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/0974-7753.203171","article-title":"Anagen effluvium following acute colchicine poisoning","volume":"8","author":"Combalia","year":"2016","journal-title":"Int J Trichol"},{"issue":"7","key":"10.1016\/j.jaad.2020.08.006_bib112","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1097\/PEC.0000000000001530","article-title":"Dermatologic manifestations of colchicine intoxication","volume":"34","author":"G\u00fcrkan","year":"2018","journal-title":"Pediatr Emerg Care"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib113","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1542\/peds.109.5.971","article-title":"Late diagnosis of severe colchicine intoxication","volume":"109","author":"G\u00fcven","year":"2002","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.006_bib114","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.0303-6987.2006.00393.x","article-title":"Colchicine intoxication diagnosed in a skin biopsy: a case report","volume":"33","author":"Mason","year":"2006","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.006_bib115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.2004.05838.x","article-title":"Toxic epidermal necrolysis-like reaction secondary to colchicine overdose","volume":"150","author":"Arroyo","year":"2004","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.006_bib116","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib117","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4103\/0378-6323.184199","article-title":"Anticoagulants in dermatology","volume":"82","author":"Adya","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.006_bib118","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1203475417716364","article-title":"Adverse drug reactions and cutaneous manifestations associated with anticoagulation","volume":"21","author":"Vu","year":"2017","journal-title":"J Cutan Med Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220323586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220323586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:55:44Z","timestamp":1759272944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220323586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0190962220323586"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.006","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}